{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:35:45Z","timestamp":1787798145995,"version":"build-2784847793"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T00:00:00Z","timestamp":1627084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T00:00:00Z","timestamp":1627084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1038\/s41375-021-01360-9","type":"journal-article","created":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T12:02:37Z","timestamp":1627128157000},"page":"292-295","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFR"],"prefix":"10.1038","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6930-2416","authenticated-orcid":false,"given":"Sena","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kidist","family":"Ashami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sora","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Staser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Vij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Santhanam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Ritchey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7656-0982","authenticated-orcid":false,"given":"Matthew A.","family":"Ciorba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0429-3133","authenticated-orcid":false,"given":"John F.","family":"DiPersio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5590-087X","authenticated-orcid":false,"given":"Jaebok","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,24]]},"reference":[{"key":"1360_CR1","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nri2000","volume":"7","author":"WD Shlomchik","year":"2007","unstructured":"Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7:340\u201352.","journal-title":"Nat Rev Immunol."},{"key":"1360_CR2","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.1182\/blood-2012-01-403196","volume":"120","author":"J Choi","year":"2012","unstructured":"Choi J, Ziga ED, Ritchey J, Collins L, Prior JL, Cooper ML, et al. IFNgammaR signaling mediates alloreactive T-cell trafficking and GVHD. Blood. 2012;120:4093\u2013103.","journal-title":"Blood."},{"key":"1360_CR3","doi-asserted-by":"publisher","first-page":"e109799","DOI":"10.1371\/journal.pone.0109799","volume":"9","author":"J Choi","year":"2014","unstructured":"Choi J, Cooper ML, Alahmari B, Ritchey J, Collins L, Holt M, et al. Pharmacologic blockade of JAK1\/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. PLoS One. 2014;9:e109799.","journal-title":"PLoS One."},{"key":"1360_CR4","doi-asserted-by":"publisher","first-page":"35721","DOI":"10.18632\/oncotarget.26291","volume":"9","author":"K Ashami","year":"2018","unstructured":"Ashami K, DiPersio JF, Choi J. Targeting IFNGR\/IL6R or downstream JAK1\/JAK2 to control GvHD. Oncotarget. 2018;9:35721\u20132.","journal-title":"Oncotarget."},{"key":"1360_CR5","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1038\/s41375-018-0123-z","volume":"32","author":"J Choi","year":"2018","unstructured":"Choi J, Cooper ML, Staser K, Ashami K, Vij KR, Wang B, et al. Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. Leukemia. 2018;32:2483\u201394.","journal-title":"Leukemia."},{"key":"1360_CR6","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1038\/sj.onc.1203523","volume":"19","author":"JX Lin","year":"2000","unstructured":"Lin JX, Leonard WJ. The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene. 2000;19:2566\u201376.","journal-title":"Oncogene."},{"key":"1360_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1074-7613(00)80025-4","volume":"10","author":"R Moriggl","year":"1999","unstructured":"Moriggl R, Topham DJ, Teglund S, Sexl V, McKay C, Wang D, et al. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity. 1999;10:249\u201359.","journal-title":"Immunity."},{"key":"1360_CR8","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1172\/JCI90592","volume":"127","author":"JL Ferrara","year":"2017","unstructured":"Ferrara JL, Smith CM, Sheets J, Reddy P, Serody JS. Altered homeostatic regulation of innate and adaptive immunity in lower gastrointestinal tract GVHD pathogenesis. J Clin Invest. 2017;127:2441\u201351.","journal-title":"J Clin Invest."},{"key":"1360_CR9","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/bmt.2014.69","volume":"49","author":"C Castilla-Llorente","year":"2014","unstructured":"Castilla-Llorente C, Martin PJ, McDonald GB, Storer BE, Appelbaum FR, Deeg HJ, et al. Prognostic factors and outcomes of severe gastrointestinal GVHD after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2014;49:966\u201371.","journal-title":"Bone Marrow Transplant."},{"key":"1360_CR10","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1038\/s41375-020-0786-0","volume":"34","author":"B Alahmari","year":"2020","unstructured":"Alahmari B, Cooper ML, Vij K, Ritchey J, Ruminski P, Gao F, et al. Selective targeting of \u03b14\u03b21 integrin attenuates murine graft versus host disease. Leukemia. 2020;34:3100\u20134.","journal-title":"Leukemia."},{"key":"1360_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.immuni.2019.06.003","volume":"51","author":"YY Fu","year":"2019","unstructured":"Fu YY, Egorova A, Sobieski C, Kuttiyara J, Calafiore M, Takashima S, et al. T cell recruitment to the intestinal stem cell compartment drives immune-mediated intestinal damage after allogeneic transplantation. Immunity. 2019;51:90\u2013103. e3","journal-title":"Immunity."},{"key":"1360_CR12","first-page":"2089","volume":"143","author":"S Barberan","year":"2016","unstructured":"Barberan S, Fraguas S, Cebria F. The EGFR signaling pathway controls gut progenitor differentiation during planarian regeneration and homeostasis. Development. 2016;143:2089\u2013102.","journal-title":"Development."},{"key":"1360_CR13","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1146\/annurev-physiol-021115-105447","volume":"79","author":"E Aihara","year":"2017","unstructured":"Aihara E, Engevik KA, Montrose MH. Trefoil factor peptides and gastrointestinal function. Annu Rev Physiol. 2017;79:357\u201380.","journal-title":"Annu Rev Physiol."},{"key":"1360_CR14","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/1535-7163.MCT-13-0367","volume":"13","author":"JL Martin","year":"2014","unstructured":"Martin JL, de Silva HC, Lin MZ, Scott CD, Baxter RC. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade. Mol Cancer Ther. 2014;13:316\u201328.","journal-title":"Mol Cancer Ther."},{"key":"1360_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.brainres.2015.03.023","volume":"1611","author":"B Liu","year":"2015","unstructured":"Liu B, Guo Z, Dong H, Daofeng T, Cai Q, Ji B, et al. LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2. Brain Res. 2015;1611:93\u2013100.","journal-title":"Brain Res."}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01360-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01360-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01360-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T23:10:20Z","timestamp":1641337820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01360-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,24]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1360"],"URL":"https:\/\/doi.org\/10.1038\/s41375-021-01360-9","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,24]]},"assertion":[{"value":"12 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JC received honorarium from Incyte Corporation, received research funding from Mallinckrodt Pharmaceuticals, and served as a consultant for Daewoong Pharmaceutical. JFD served on advisory boards for Incyte Corporation, CellWorks, Macrogenics, Amphivena, Arch, Rivervest, and Bioline and is a co-Founder of Magenta Therapeutics and WUGen. MLC is a co-Founder and Chief Scientific Officer of WUgen. MAC previously had research grants from Incyte Corporation. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}